| PRECLINICAL | evidence | Semaglutide in peripheral artery disease and diabetes by baseline disease severity and age: the STRIDE trial. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Correction: Discontinuation of oral semaglutide due to adverse effects: a database study on Japanese individuals with type 2 diabetes. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Knowledge, Attitudes and Practices on the Use of Antidiabetic Medications for Weight Loss: A Cross-Sectional Study in the Lebanese Population. | Semaglutide | Weight & fat loss | 2026-07-01 |
| PRECLINICAL | evidence | Effects of GLP-1 Receptor Agonists on Psoriasis: An "Agent-Specific" Systematic Review of the Literature. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Effectiveness and Safety of Semaglutide in Type 1 Diabetes: A Danish Nationwide Cohort Study (2018-2024). | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials. | Semaglutide | Weight & fat loss | 2026-07-01 |
| PRECLINICAL | evidence | Semaglutide in metabolic dysfunction-associated alcohol-related liver disease: a potential dual-target therapy for metabolic dysfunction and alcohol use. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Atypical retrobulbar optic neuropathy after semaglutide escalation. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Repurposed Drugs and Cardiovascular Morbidity: A Cost-Effectiveness Analysis. | Semaglutide | Lipid & cardiovascular markers | 2026-07-01 |
| PRECLINICAL | evidence | Glucagon-Like Peptide-1 Receptor Agonists in Orthopedics: A Scoping Review of Emerging Applications. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Hormonal Contraception and Initiation of Semaglutide Therapy. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | When Side Effects Become Therapies: A Mechanistic Taxonomy of Adverse Drug Reactions as Translational Signals for Drug Repositioning. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Hypersensitivity Reaction to Tirzepatide With Demonstrated Tolerance to Semaglutide: A Case Report. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Dose-Response and Clinical Equivalence of Semaglutide and Tirzepatide for Weight Loss in Type 2 Diabetes: A Model-Based Analysis. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Dulaglutide in the era of tirzepatide and semaglutide: reaffirming its role in contemporary cardiometabolic care. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Body Composition Changes During GLP-1 Receptor Agonist Therapy in Pediatric Obesity: A Pilot Study. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | The Ethics of Wegovy in Pediatric Mental Health. | Ozempic | Weight & fat loss | 2026-07-01 |
| PRECLINICAL | evidence | Letter: Beyond Feasibility-The Need for Longer Duration and Composite NIT Endpoints in Biopsy-Free MASH Trials: Authors' Reply. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Sustained Glycaemic Control and Preserved Beta-Cell Function in Newly Diagnosed Type 1 Diabetes Treated With Semaglutide. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | GLP-1-based therapy and ICD-10-documented heart failure or respiratory failure events in non-diabetic adults with rheumatoid arthritis and obesity: a TriNetX federated cohort study. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Simultaneous bilateral NAION following initiation of high-dose semaglutide: a case report. | semaglutida | Glycemic control | 2026-07-01 |
| PRECLINICAL | evidence | Reestimation of Medicare Spending for Semaglutide After Most Favored Nation and Medicare Drug Price Negotiation Announcements. | Ozempic | Glycemic control | 2026-07-01 |
| PRECLINICAL | evidence | Cardiometabolic Profiles of Oral and Subcutaneous Glucagon-Like Peptide-1 Receptor Mono-Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta-Analysis. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review. | Semaglutide | Weight & fat loss | 2026-07-01 |
| PRECLINICAL | evidence | American Society for Metabolic and Bariatric Surgery statement on the treatment options for patients with non-response and weight recurrence after metabolic and bariatric surgery. | Semaglutide | Weight & fat loss | 2026-07-01 |
| PRECLINICAL | evidence | What the Scale Does Not Show: A Patient's Reflection on Semaglutide, Strength, and the SMART Trial. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Glucagon-like peptide-1 receptor agonists in rheumatoid arthritis. | Semaglutide | Glycemic control | 2026-07-01 |
| PRECLINICAL | evidence | Use of Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study. | Semaglutide | Glycemic control | 2026-07-01 |
| PRECLINICAL | evidence | LY6D promotes hepatic steatosis via the GRB2-AMPK-SREBP1 signaling axis. | Semaglutide | Liver health | 2026-07-01 |
| PRECLINICAL | evidence | Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial. | Semaglutide | — | 2026-06-30 |
| PRECLINICAL | evidence | Assessing the risk of diabetic retinopathy progression with GLP-1 receptor agonists: a systematic review and meta-analysis. | Semaglutide | — | 2026-06-30 |
| PRECLINICAL | evidence | Real-World Comparative Effectiveness of Tirzepatide and Semaglutide for Obesity: A Multicentered Study. | Semaglutide | — | 2026-06-30 |
| PRECLINICAL | evidence | Discovery of DDO-4279 as a PP5 degrader for the treatment of obesity. | Semaglutide | — | 2026-06-30 |
| PRECLINICAL | evidence | Weight loss and gut microbial changes associated with semaglutide among people living with schizophrenia receiving clozapine or olanzapine: An open-label 24-week semaglutide intervention and 76-week trial. | Semaglutide | — | 2026-06-29 |
| PRECLINICAL | evidence | Neuropsychiatric association of tirzepatide and semaglutide in obesity with and without type 2 diabetes. | Semaglutide | — | 2026-06-29 |
| PRECLINICAL | evidence | Engineered circular RNA compatible with complete nucleoside modification and rolling circle translation through a Cap-independent translation enhancer. | Semaglutide | — | 2026-06-29 |
| PRECLINICAL | evidence | Comparison in the Use of Regulatory Pathways Between Health Canada and the Food and Drug Administration: A Cross-sectional Study. | Semaglutide | — | 2026-06-29 |
| PRECLINICAL | evidence | [Insulin intoxications caused by falsified semaglutide]. | Semaglutide | Glycemic control | 2026-06-29 |
| PRECLINICAL | evidence | Structure-aware fragment assignment for interpreting tandem mass spectrometry of modified and cyclic peptides. | Semaglutide | — | 2026-06-29 |
| PRECLINICAL | evidence | [The role of obesity and weight reduction in obstructive sleep apnea]. | Semaglutide | Weight & fat loss | 2026-06-28 |
| PRECLINICAL | evidence | Ease of Use, Ease of Learning, and Convenience of the CagriSema Dual-Chamber Pen: Results From a Usability Study in Adults With Overweight, Obesity, or Type 2 Diabetes. | Semaglutide | — | 2026-06-28 |
| PRECLINICAL | evidence | Real-World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan. | Semaglutide | — | 2026-06-28 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonists and the Ocular Surface: A Narrative Review of Restoration, Remodeling, and Clinical Implications. | Semaglutide | — | 2026-06-28 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonists in Adolescents: Emerging Endocrine, Reproductive, and Psychosocial Concerns. | Semaglutide | — | 2026-06-28 |
| PRECLINICAL | evidence | Beyond Weight Loss: Early Real-World Evidence of Semaglutide in Obesity. | Semaglutide | — | 2026-06-28 |
| PRECLINICAL | evidence | The silent rise of self-prescribed semaglutide use among non-obese young adults in the Middle East. | Semaglutide | — | 2026-06-28 |
| PRECLINICAL | evidence | Secondary alopecia due to semaglutide. | semaglutida | — | 2026-06-27 |
| PRECLINICAL | evidence | From dual to quintuple agonism for next-generation pharmacology to treat obesity and type 2 diabetes: synergistic incretin and nuclear receptor signaling. | Semaglutide | — | 2026-06-26 |